Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)
BACKGROUND
Use of tacrolimus (FK506), a potent immunosuppressive agent, has been reported to have a 10-20% incidence of insulin-dependent diabetes mellitus (IDDM) in adults, but the incidence of IDDM in pediatric renal transplant recipients treated with this agent is unknown. In this article, we report our single-center experience with FK506-induced IDDM in children.


METHODS
Five consecutive living related donor pediatric renal transplants were reviewed retrospectively.


RESULTS
All five patients developed IDDM lasting longer than 6 months. Mean follow-up time was 18.6 months.


CONCLUSIONS
Pediatric patients may be at high risk for developing FK506-induced IDDM.
Moxey-Mims
M M
MM
Department of Nephrology, Children's National Medical Center, Washington, DC 20010, USA.
Kay
C
C
Light
J A
JA
Kher
K K
KK
D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016030:Kidney Transplantation; D016559:Tacrolimus / Q000009:adverse effects*
D016559:Tacrolimus